BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38433502)

  • 1. Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase.
    Tishova Y; Kalinchenko S; Mskhalaya G; Hackett G; Livingston M; König C; Strange R; Zitzmann M; Mann A; Maarouf A; Ramachandran S
    Diabetes Obes Metab; 2024 Jun; 26(6):2147-2157. PubMed ID: 38433502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus.
    Gopal RA; Bothra N; Acharya SV; Ganesh HK; Bandgar TR; Menon PS; Shah NS
    Endocr Pract; 2010; 16(4):570-6. PubMed ID: 20150021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ; Doros G; Hammerer PG; Yassin AA
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P;
    J Sex Med; 2014 Mar; 11(3):840-56. PubMed ID: 24308723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
    Kapoor D; Goodwin E; Channer KS; Jones TH
    Eur J Endocrinol; 2006 Jun; 154(6):899-906. PubMed ID: 16728551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
    Hackett G
    Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency.
    Haider KS; Zitzmann M; Ramachandran P; König CS; Hackett G; Haider A; Saad F; Desnerck P; Strange R; Mann A; Ramachandran S
    Aging Male; 2024 Dec; 27(1):2357548. PubMed ID: 38812251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes.
    Groti K; Žuran I; Antonič B; Foršnarič L; Pfeifer M
    Aging Male; 2018 Sep; 21(3):158-169. PubMed ID: 29708829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism.
    Naharci MI; Pinar M; Bolu E; Olgun A
    Endocr Pract; 2007 Oct; 13(6):629-35. PubMed ID: 17954419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of testosterone replacement therapy on insulin sensitivity and body composition in congenital hypogonadism: A prospective longitudinal follow-up study.
    Reddy KC; Yadav SB
    J Postgrad Med; 2021; 67(2):67-74. PubMed ID: 33942770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone undecanoate improves lipid profile in patients with type 1 diabetes and hypogonadotrophic hypogonadism.
    Chillarón JJ; Fernández-Miró M; Albareda M; Fontserè S; Colom C; Vila L; Pedro-Botet J; Flores Le-Roux JA
    Endocr J; 2016 Sep; 63(9):849-855. PubMed ID: 27452372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
    Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
    Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
    Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
    J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.